文献速递血栓与止血

获得性与先天性血友病A中抗凝血因子VIII C1结构域抗体的频率及表位特异性

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
PubMed 文献 · Blood · 2017-05-15

本研究分析了178例获得性与先天性血友病A抑制物患者中抗C1结构域抗体的频率和表位特异性。采用同源扫描突变和HSA融合蛋白检测,发现A2、C1、C2特异性抗体在获得性血友病A患者(n=115)中分别占23%、78%、68%,在先天性血友病A抑制物患者(n=63)中分别占52%、57%、81%。C1结构域在获得性与先天性血友病A的体液抗fVIII免疫反应中均有显著贡献。

要点

  • 获得性血友病A患者中C1特异性抗体占78%,先天性血友病A抑制物患者中占57%。
  • HSA-fVIII结构域蛋白检测较同源扫描突变法检出率更高,因抗体与人及猪fVIII交叉反应导致HSM假阴性。
  • LE2E9样和2A9样抗体在获得性血友病A患者中贡献尤为显著。

核心结论

  • C1结构域与A2和C2结构域一样,在获得性与先天性血友病A抑制物患者的体液抗fVIII免疫反应中贡献显著。

研究设计与样本

  • 研究纳入获得性与先天性血友病A抑制物患者共178例,其中获得性血友病A患者115例,先天性血友病A抑制物患者63例。
  • 采用同源扫描突变法(HSM)结合单一人结构域人/猪fVIII蛋白,以及抗体与人血清白蛋白(HSA)融合的A2、C1、C2结构域蛋白结合实验分析抗体结构域特异性。

主要发现

  • A2、C1、C2特异性抗体在获得性血友病A患者(n=115)中检出率分别为23%、78%、68%,在先天性血友病A抑制物患者(n=63)中分别为52%、57%、81%。
  • HSA-fVIII结构域蛋白检测证实了HSM结果,但检出水平更高,原因是抗体与人及猪fVIII交叉反应导致HSM假阴性结果。
  • 人单克隆抗体LE2E9竞争结合实验显示其与鼠C1特异性A组单克隆抗体(包括2A9)表位重叠。
  • 突变分析鉴定出LE2E9的关键结合残基为E2066,2A9为F2068,这些残基也被血友病患者体内的抗C1抗体识别。
  • LE2E9样和2A9样抗体的强贡献尤其在获得性血友病A患者中观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several studies showed that neutralizing anti-factor VIII (anti-fVIII) antibodies (inhibitors) in patients with acquired hemophilia A (AHA) and congenital hemophilia A (HA) are primarily directed to the A2 and C2 domains. In this study, the frequency and epitope specificity of anti-C1 antibodies were analyzed in acquired and congenital hemophilia inhibitor patients (n = 178). The domain specificity of antibodies was studied by homolog-scanning mutagenesis (HSM) with single human domain human/porcine fVIII proteins and antibody binding to human A2, C1, and C2 domains presented as human serum albumin (HSA) fusion proteins. The analysis with HSA-fVIII domain proteins confirmed the results of the HSM approach but resulted in higher detection levels. The higher detection levels with HSA-fVIII domain proteins are a result of antibody cross-reactivity with human and porcine fVIII leading to false-negative HSM results. Overall, A2-, C1-, and C2-specific antibodies were detected in 23%, 78%, and 68% of patients with AHA (n = 115) and in 52%, 57%, and 81% of HA inhibitor patients (n = 63). Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlapping epitopes with murine C1-specific group A mAbs including 2A9. Mutational analyses identified distinct crucial binding residues for LE2E9 (E2066) and 2A9 (F2068) that are also recognized by anti-C1 antibodies present in patients with hemophilia. A strong contribution of LE2E9- and 2A9-like antibodies was particularly observed in patients with AHA. Overall, our study demonstrates that the C1 domain, in addition to the A2 and C2 domains, contributes significantly to the humoral anti-fVIII immune response in acquired and congenital hemophilia inhibitor patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kahle J, Orlowski A, Stichel D, et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017. PMID: 28507083. doi:10.1182/blood-2016-11-751347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。